
















INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Atty. Docket No. 01975.0024-00				Serial No. 09/555,139			
Applicant Etienne AGSTERIBBE et al.							
Filing Date May 25, 2000				Group: 1645			
U.S. PATENT DOCUMENTS							
Examiner Initial*	Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate	
FOREIGN PATENT DOCUMENTS							
	Document Number	Date	Country	Class	Sub Class	Translation Yes or No	
	1 498 261	18 Jan 1978	Great Britain				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Hirabayashi et al., "Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination," <i>Vaccine</i> 8:243-248 (1990).						
	Kikuta et al., "Cross-protection against influenza B type virus infection by intranansal inoculation of the HA vaccines combined with cholera toxin B subunit," <i>Vaccine</i> 8:595-599 (1990).						
	Tamura et al., "Cross-Protection Against Influenza Virus Infection Afforded By Trivalent Inactivated Vaccines Inoculated Intranasally With Cholera Toxin B Subunit," <i>J. Immunology</i> 3:981-988 (1992).						
	Tamura et al., "Synergistic action of cholera toxin B subunit (and <i>Escherichia coli</i> heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine," <i>Vaccine</i> 12:419-426 (1994).						
	Tamura et al., " <i>Escherichia coli</i> heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine," <i>Vaccine</i> 12:1083-1089 (1994).						
	Davenport et al., "Comparisons of serologic and febrile responses in humans to vaccination with influenza A viruses or their hemagglutinins," <i>J. Lab. & Clin. Med.</i> 63:5-13 (1964).						
	Clancy, "Mucosal Vaccines for the Prevention of Influenza," <i>Drugs</i> 50:587-594 (1995).						
	Katz et al., "Adjuvant Activity of the Heat-Labile Enterotoxin from Enterotoxigenic <i>Escherichia coli</i> for Oral Administration of Inactivated Influenza Virus Vaccine," <i>J. Infect. Dis.</i> 175:352-363 (1997).						
	Vieira et al., "The pUC plasmids, an M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers," <i>Gene</i> 19:259-268 (1982).						
	De Haan et al., "Mucosal immunogenicity of the <i>Escherichia coli</i> heat-labile enterotoxin: role of the A subunit," <i>Vaccine</i> 14:260-266 (1996).						
Examiner 				Date Considered 1/8/02			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							
Form PTO 1449				Patent and Trademark Office - U.S. Department of Commerce			

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Atty. Docket No. 01975.0024-00				Serial No. 09/555,139			
Applicant Etienne AGSTERIBBE et al.							
Filing Date May 25, 2000				Group: 1645			
U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Sub Class	Translation Yes or No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
           		Dallas et al., "Cistrons Encoding <i>Escherichia coli</i> Heat-Labile Toxin," <i>J. Bacteriol.</i> 139:850-858 (1979).					
		Van der Linden et al., "Cytoplasmic high-level expression of a soluble, enzymatically active form of the <i>Escherichia coli</i> penicillin-binding protein 5 and purification by dye chromatography," <i>Eur. J. Biochem.</i> 204:197-202 (1992).					
		Uesaka et al., "Simple method of purification of <i>Escherichia coli</i> heat-labile enterotoxin and cholera toxin using immobilized galactose," <i>Microb. Path.</i> 16:71-76 (1994).					
		Chaloupka et al., "Comparative Analysis of Six European Influenza Vaccines," <i>Eur. J. Microbiol. Infect. Dis.</i> 15:121-127 (1996).					
		Wood et al., "An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines," <i>J. Biol. Stand.</i> 5:237-247 (1977).					
		Hashigucci et al., "Antibody responses in volunteers induced by nasal influenza vaccine combined with <i>Escherichia coli</i> heat-labile enterotoxin B subunit containing a trace amount of the holotoxin," <i>Vaccine</i> 14:113-119 (1996).					
		Nashar et al., "Current progress in the development of the B subunits of cholera toxin and <i>Escherichia coli</i> heat-labile enterotoxin as carriers for the oral delivery of heterologous antigens and epitopes," <i>Vaccine</i> 11:235-240 (1993).					
		Verweij et al., "Mucosal immunoadjuvant activity of recombinant <i>Escherichia coli</i> heat-labile enterotoxin and its B subunit: Induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen," <i>Vaccine</i> 16:2069-2076 (1998).					
Examiner 				Date Considered 1/8/02			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							
Form PTO 1449				Patent and Trademark Office - U.S. Department of Commerce			